MYGN Myriad Genetics, Inc. - Common Stock
NASDAQ · Biotechnology · View on SEC EDGAR ↗ close Oct 2, 2026 10-K/10-Q Jul 31, 2026MYGN Stock Snapshot Price, market cap, P/E, EPS, ROE, debt/equity, 52-week range
MYGN Stock Price Chart Daily OHLCV with technical indicators — pan, zoom, and customize your view
Bar granularity adapts to the selected period — hover the chart to see open/high/low/close for a bar.
| Ex-date | Split | Type |
|---|---|---|
| March 26, 2009 | 2-for-1 | Forward |
| Sept. 12, 2000 | 2-for-1 | Forward |
About Myriad Genetics, Inc. - Common Stock Company overview from Wikipedia
Myriad Genetics, Inc. is an American genetic testing and precision medicine company based in Salt Lake City, Utah, United States. Myriad employs a number of proprietary technologies that permit doctors and patients to understand the genetic basis of human disease and the role that genes play in the onset, progression and treatment of disease. This information is used to guide the development of new products that assess an individual's risk for developing disease later in life (predictive medicine), identify a patient's likelihood of responding to a particular drug therapy (precision medicine), assess a patient's risk of disease progression and disease recurrence (precision medicine), and measure disease activity.
History
The global search for the genetic basis of breast cancer began when Mary-Claire King, Ph.D., from the University of California, Berkeley announced the localization through linkage analysis of a gene associated with increased risk for breast cancer (BRCA1) to the long arm of chromosome 17.
To further locate the actual gene, Dr. Skolnick and his colleagues invented a gene mapping technique known as Restriction Fragment-length Polymorphisms (RFLP). Gilbert joined Kimberlin in 1991, and they teamed up with Skolnick to form Myriad Genetics.
In August 1994, Mark Skolnick and researchers at Myriad, along with colleagues at the University of Utah, the U.S. National Institutes of Health (NIH), and McGill University sequenced BRCA1. They attempted to patent this gene, which resulted in significant controversy and a landmark Supreme Court Case.
The firm then established the first clinical laboratory to commercialize genomic testing. Myriad created the first test to measure the molecular biology and aggressiveness of men’s prostate cancer, devised a method to assess the inherited breast cancer risk of any woman not previously diagnosed with breast cancer, regardless of ancestry, important for addressing racial and ethnic disparities, commercialized a psychotropic test that covers 61 medications commonly prescribed for depression, anxiety, ADHD. Also pioneering the field of DNA-specific medicine, Myriad received the first FDA approval for a lab-developed diagnostic test for use in predicting the responses to a DNA-repair drug.
Acquisitions and subsidiaries
In August 2016, Myriad announced it would acquire Assurex Health for up to $410 million, expanding the company's genetic testing for psychotropic medicine selection.
In July 2018, Myriad completed an acquisition of reproductive genetic testing firm Counsyl for $375 million, expanding the company's testing capabilities to carrier and prenatal screening.
Other subsidiaries of Myriad Genetics include Myriad International and Myriad Autoimmune (aka Crescendo Bioscience).
Founders
The founders of Myriad are Peter Meldrum (past President and CEO of Agridyne and past CEO and President of Myriad Genetics, Inc.) and Mark Skolnick (Adjunct Professor in the Department of Medical Informatics at the University of Utah).
Products
Among the prognostic tests developed and marketed by Myriad is "Prolaris", which uses gene expression profiling to provide a 10-year prostate cancer-specific risk of death. Another prognostic test, marketed as "myRisk Hereditary Cancer", reviews genetic markers correlated with elevated risk of developing any of eleven hereditary cancers.
Controversies
Myriad Genetics's patents on human genes became quite controversial. Following the discovery by Mary-Claire King that a gene on chromosome 17 is associated with an increased risk of breast cancer, Myriad attempted to patent this gene. These patents were the subject of scrutiny after Myriad became involved in a lawsuit over its patenting practices, which led to the landmark Supreme Court decision Association for Molecular Pathology v. Myriad Genetics, Inc. which ruled these patents illegal. Because genes occur naturally in every human, in addition to raising moral questions, some believe that patents constitute an obstacle to biomedical research worldwide. Additionally, the discovery of their relevance to breast cancer was funded by the public.
Patent lawsuits
In 2010–2013 Myriad Genetics was a defendant in the case Association for Molecular Pathology v. Myriad Genetics (formerly Association For Molecular Pathology et al. v. United States Patent and Trademark Office).
Lawyers at the ACLU served as counsel for the plaintiffs. In the suit, medical associations, doctors, and patients sued Myriad Genetics to challenge seven United States patents on genes related to breast cancer and ovarian cancer.
Two of the company's patents on the BRCA1 and BRCA2 genes, which are inherited gene mutations that link to around half of the 5%–10% of inherited gene mutating breast cancer cases in the US[27], were ruled invalid on March 29, 2010, by Judge Robert W. Sweet in the U.S. District Court for the Southern District of New York. On appeal, the Court of Appeals for the Federal Circuit reversed the trial court in an opinion dated July 29, 2011 and held that the genes were eligible for patents. On December 7, 2011, the ACLU filed a petition for a writ of certiorari to the Supreme Court. On March 26, 2012, the Supreme Court vacated the Federal Circuit's judgment and remanded the case for further consideration in light of Mayo Collaborative Services v. Prometheus Laboratories, Inc., in which the Supreme Court had ruled, just six days earlier, that more restrictive rules were required to patent observations about natural phenomena.
On August 16, 2012, the Federal Circuit reaffirmed Myriad's right to patent the genes (because isolated genes are different from their natural state, using its own precedent in Amgen v. Chugai Pharmaceutical), although they denied patent claims on methods comprising comparison of DNA sequences, as unpatentable "mental acts". On November 30, 2012, the Supreme Court agreed to hear a second challenge to the two gene patents held by Myriad. Oral argument took place on April 15, 2013. On June 13, 2013, in Association for Molecular Pathology v. Myriad Genetics (No. 12-398), the US Supreme Court unanimously ruled that "A naturally occurring DNA segment is a product of nature and not patent eligible merely because it has been isolated", invalidating Myriad's patents on the BRCA1 and BRCA2 genes. However, the Court also held that manipulation of a gene to create something not found in nature—such as a strand of synthetically-produced complementary DNA (cDNA)—could still be eligible for patent protection.
Myriad Genetics has also been involved in litigation in Australia over the patentability of DNA sequences (D'Arcy v Myriad Genetics Inc (2015)). Regarding BRCA1, the company succeeded in the Federal Court, both at first instance and on appeal to the full court, but in October 2015 lost in a unanimous decision of the High Court, D'Arcy v Myriad Genetics Inc.
Source: Wikipedia, CC BY-SA 4.0 · View on Wikipedia ↗
10-Year Performance Revenue, net income, margins and EPS trends
Valuation P/E, P/S, P/B, EV/EBITDA ratios — is the stock expensive or cheap?
| Metric | 5Y trend | MYGN | 5Y avg | Peer Median | Verdict |
|---|---|---|---|---|---|
| P/E (TTM) | -3.85Y avg ≈-21.3 | ≈-21.3 | · | · | |
| P/S (TTM) | 0.55Y avg ≈1.9 | ≈1.9 | 16.4 | Undervalued | |
| P/B (MRQ) | 1.45Y avg ≈1.8 | ≈1.8 | 2.3 | Undervalued | |
| EV / EBITDA | -1.05Y avg ≈-6.8 | ≈-6.8 | · | · | |
| Price / Cash Flow | 235.85Y avg ≈54.1 | ≈54.1 | · | · | |
| EV / Revenue | 0.55Y avg ≈1.7 | ≈1.7 | · | · | |
| Price / Tangible Book (MRQ) | 2.65Y avg ≈7.1 | ≈7.1 | · | · |
Peer median is calculated on a standardized basis per metric and may not always match the TTM/MRQ basis shown for this stock.
Profitability Gross, operating and net margins; ROE, ROA, ROIC
| Metric | 5Y trend | MYGN | 5Y avg | Peer Median | Verdict |
|---|---|---|---|---|---|
| Gross Margin (TTM) | 68.8% | · | · | · | |
| Operating Margin (TTM) | -12.2%5Y avg ≈-28.8% | ≈-28.8% | -540.4% | Top tier | |
| EBITDA Margin | -47.0%5Y avg ≈-28.8% | ≈-28.8% | -540.4% | Top tier | |
| Pretax Margin (TTM) | -13.9%5Y avg ≈-25.3% | ≈-25.3% | -482.4% | Top tier | |
| Net Profit Margin (TTM) | -14.0%5Y avg ≈-23.0% | ≈-23.0% | -514.6% | Top tier | |
| ROA (TTM) | -17.1%5Y avg ≈-17.4% | ≈-17.4% | -36.2% | Weak | |
| ROE (TTM) | -32.5%5Y avg ≈-33.2% | ≈-33.2% | -67.8% | Weak | |
| ROIC | -73.5%5Y avg ≈-28.8% | ≈-28.8% | -45.0% | Weak |
Financial Health Debt, liquidity, solvency — balance sheet strength
| Metric | 5Y trend | MYGN | 5Y avg | Peer Median | Verdict |
|---|---|---|---|---|---|
| Debt / Equity (MRQ) | 0.45Y avg ≈0.1 | ≈0.1 | 0.0 | High debt | |
| Current Ratio (MRQ) | 2.25Y avg ≈2.1 | ≈2.1 | 5.9 | Low liquidity | |
| Quick Ratio | 2.05Y avg ≈1.7 | ≈1.7 | 5.6 | Low liquidity | |
| Long-Term Debt / Equity (MRQ) | 0.45Y avg ≈0.1 | ≈0.1 | 0.0 | High debt |
Growth Revenue, EPS and net income growth: YoY, 3Y CAGR, 5Y CAGR
| Metric | 5Y trend | MYGN | 5Y avg | Peer Median | Verdict |
|---|---|---|---|---|---|
| Revenue YoY | -1.6%5Y avg ≈8.6% | ≈8.6% | · | · | |
| Revenue CAGR 3Y | 6.7%5Y avg ≈8.0% | ≈8.0% | · | · | |
| Revenue CAGR 5Y | 8.2% | · | · | · |
Capital Efficiency Asset turnover, inventory turnover, receivables turnover
| Metric | 5Y trend | MYGN | 5Y avg | Peer Median | Verdict |
|---|---|---|---|---|---|
| Asset Turnover | 1.05Y avg ≈0.7 | ≈0.7 | 0.3 | Top tier | |
| Inventory Turnover | 8.5 | · | · | · | |
| Receivables Turnover | 7.05Y avg ≈7.1 | ≈7.1 | 10.5 | Weak | |
| Revenue / Employee | ≈$305.4K | · | · | · |
value · ≈ 5Y avg · industry median · verdict relative to median
Dividends Yield, payout ratio, dividend history, 5Y CAGR
| Ex-date | Amount | Currency | Yield |
|---|---|---|---|
| Jul 1, 2009 | $1.75 | USD | ≈13.5% |
| Jun 15, 2009 | $1.75 | USD | ≈4.9% |
Earnings History EPS actual vs estimate, surprise %, beat rate, next earnings date
| Period | Report | EPS Actual | EPS Est | Surprise |
|---|---|---|---|---|
| June 30, 2026 | Aug 3, 2026 | $-0.25 | $-0.06 | -323.7% |
| March 31, 2026 | $-0.09 | $-0.07 | -28.9% | |
| Dec. 31, 2025 | $0.04 | $-0.01 | 368.5% | |
| Sept. 30, 2025 | $0.00 | $-0.01 | — | |
| June 30, 2025 | $0.05 | $-0.01 | — | |
| March 31, 2025 | $-0.03 | $-0.06 | 49.8% |
Full Fundamentals All metrics by year — income statement, balance sheet, cash flow
Income Statement
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $824M | $838M | $753M | $678M | $691M | $557M | $851M | $744M | $729M | $740M | $722M | |
| Cost of Revenue | $248M | $252M | $236M | $202M | · | · | · | · | $145M | $133M | $133M | |
| Gross Profit | $577M | $585M | $517M | $476M | · | · | · | · | · | · | · | |
| R&D Expense | $107M | $113M | $89M | $85M | $82M | $73M | $86M | $71M | $74M | $71M | $76M | |
| SG&A Expense | $257M | $276M | $284M | $248M | $538M | $497M | $557M | $435M | $440M | $359M | $366M | |
| Operating Expenses | $964M | $709M | $774M | $617M | $881M | $847M | $844M | $622M | $685M | $587M | $589M | |
| Operating Income | $-387M | $-124M | $-257M | $-141M | $-190M | $-290M | $8M | $122M | $44M | $153M | $134M | |
| Interest Expense | · | · | $3M | $3M | $7M | $11M | $12M | $3M | $6M | $300.0K | $200.0K | |
| Interest Income | $2M | $2M | $2M | $3M | $700.0K | $2M | $3M | $2M | $1M | $900.0K | $400.0K | |
| Other Non-op | $800.0K | $1M | $-4M | $600.0K | $139M | $15M | $1M | $-400.0K | $-3M | $2M | $500.0K | |
| Pretax Income | $-395M | $-124M | $-262M | $-141M | $-57M | $-284M | $0 | $120M | $36M | $156M | $134M | |
| Income Tax | $-29M | $4M | $1M | $-29M | $-30M | $-60M | $-4M | $-13M | $19M | $39M | $54M | |
| Net Income | $-366M | $-127M | $-263M | $-112M | $-27M | $-224M | $5M | $133M | $17M | $117M | $80M | |
| EPS (Basic) | $-3.95 | $-1.41 | $-3.18 | $-1.39 | $-0.35 | $-2.99 | $0.06 | $1.92 | $0.25 | $1.67 | $1.12 | |
| EPS (Diluted) | $-3.95 | $-1.41 | $-3.18 | $-1.39 | $-0.35 | $-2.99 | $0.06 | $1.85 | $0.25 | $1.60 | $1.07 | |
| Shares (Basic) | 92,600,000 | 90,600,000 | 82,800,000 | 80,600,000 | 78,000,000 | 74,800,000 | 73,500,000 | 69,400,000 | 68,300,000 | 70,000,000 | 71,300,000 | |
| Shares (Diluted) | 92,600,000 | 90,600,000 | 82,800,000 | 80,600,000 | 78,000,000 | 74,800,000 | 76,000,000 | 72,000,000 | 68,800,000 | 73,400,000 | 74,500,000 | |
| EBITDA | $-387M | $-124M | $-257M | $-141M | $-190M | · | $8M | $119M | $49M | $167M | · |
Balance Sheet
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $150M | $102M | $132M | $57M | $257M | $117M | $93M | $111M | $102M | $68M | $64M | |
| Short-term Investments | · | $0 | $9M | $58M | $81M | $34M | $44M | $70M | $48M | $90M | $81M | |
| Receivables | $115M | $121M | $114M | $102M | $91M | $90M | $134M | $100M | $89M | $92M | $86M | |
| Inventory | $31M | $28M | $22M | $20M | $15M | $27M | $31M | $34M | $42M | $38M | $25M | |
| Prepaid Expense | $25M | $30M | $19M | $20M | $21M | $14M | · | · | · | · | · | |
| Current Assets | $333M | $298M | $314M | $275M | $485M | $389M | $349M | $328M | $302M | $314M | $284M | |
| PP&E (Net) | $114M | $117M | $119M | $83M | $44M | $41M | $57M | $43M | $51M | $58M | $67M | |
| PP&E (Gross) | $202M | $227M | $239M | $193M | $150M | $154M | $169M | $157M | $148M | $142M | $138M | |
| Accum. Depreciation | $88M | $110M | $120M | $109M | $107M | $113M | $112M | $114M | $97M | $83M | $71M | |
| Goodwill | $52M | $286M | $287M | $287M | $239M | $329M | $417M | $319M | $316M | $195M | $177M | |
| Intangibles | $153M | $262M | $350M | $380M | $404M | $576M | $685M | $455M | $492M | $228M | $193M | |
| Other Non-current Assets | $6M | $8M | $15M | $16M | $8M | $2M | · | · | · | $5M | $5M | |
| Total Assets | $707M | $1.03B | $1.15B | $1.20B | $1.32B | $1.42B | $1.56B | $1.18B | $1.21B | $880M | $766M | |
| Accounts Payable | $30M | $32M | $26M | $29M | $30M | $20M | $33M | $26M | $22M | $21M | $21M | |
| Accrued Liabilities | $97M | $119M | $114M | $94M | $162M | $79M | $79M | $68M | $66M | $50M | $46M | |
| Current Liabilities | $134M | $164M | $156M | $137M | $204M | $146M | $118M | $102M | $218M | $72M | $69M | |
| Capital Leases | $83M | $88M | $97M | $131M | $79M | $51M | · | · | · | · | · | |
| Deferred Tax | · | · | · | $4M | $36M | $71M | $83M | $57M | $79M | $18M | $200.0K | |
| Other Non-current Liabilities | $2M | $2M | $41M | $18M | $6M | $15M | $8M | $6M | $7M | $8M | $4M | |
| Total Liabilities | $339M | $326M | $363M | $313M | $353M | $538M | $474M | $209M | $441M | $132M | $104M | |
| Long-term Debt | $120M | $40M | · | $0 | $0 | $225M | $234M | $9M | $99M | · | · | |
| Total Debt | $120M | $40M | $38M | · | $0 | · | $234M | $9M | · | · | · | |
| Common Stock | $900.0K | $900.0K | $900.0K | $800.0K | $800.0K | $800.0K | $700.0K | $700.0K | $700.0K | $700.0K | $700.0K | |
| Paid-in Capital | · | · | · | · | · | · | · | · | · | · | $745M | |
| Retained Earnings | $-1.12B | $-757M | $-630M | $-366M | $-254M | $-227M | $26M | $54M | $-79M | $-73M | $-77M | |
| AOCI | $800.0K | $-800.0K | $-4M | $-9M | $-5M | $-2M | $-5M | $-4M | $-6M | $-10M | $-7M | |
| Stockholders' Equity | $368M | $701M | $783M | $886M | $968M | $881M | $1.09B | $966M | $768M | $740M | $662M | |
| Liabilities + Equity | $707M | $1.03B | $1.15B | $1.20B | $1.32B | $1.42B | $1.56B | $1.18B | $1.21B | $880M | $766M | |
| Shares Outstanding | 93,500,000 | 91,300,000 | 89,900,000 | 81,200,000 | 80,000,000 | 75,400,000 | 73,500,000 | 70,600,000 | 68,400,000 | 69,100,000 | 68,900,000 |
Cash Flow
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $54M | $61M | $62M | $53M | $63M | · | $73M | $54M | $48M | $27M | $25M | |
| Stock-based Comp | $35M | $50M | $41M | $38M | $36M | · | $34M | $27M | $30M | $32M | $46M | |
| Deferred Tax | $1M | $-2M | $-4M | $-30M | $-32M | · | $20M | $-23M | $1M | $13M | $-4M | |
| Amort. of Intangibles | $35M | $42M | $43M | $41M | $51M | · | $59M | $37M | $33M | $13M | $13M | |
| Operating Cash Flow | $2M | $-9M | $-111M | $-106M | $19M | · | $84M | $116M | $106M | $166M | $140M | |
| CapEx | · | · | · | $45M | $18M | · | $9M | $8M | $6M | $5M | $24M | |
| Investing Cash Flow | $-27M | $-12M | $32M | $-78M | $274M | · | $-286M | $-12M | $-146M | $-91M | · | |
| Stock Repurchased | · | · | · | · | $0 | · | $50M | · | $32M | $163M | $211M | |
| Net Stock Activity | · | · | · | · | $0 | · | $-50M | · | $-32M | $-163M | · | |
| Financing Cash Flow | $64M | $-7M | $153M | $-8M | $-151M | · | $182M | $-95M | $72M | $-68M | · | |
| Net Change in Cash | $39M | $-29M | $74M | $-192M | $142M | · | $-18M | $8M | $34M | $4M | $-700.0K | |
| Free Cash Flow | · | · | · | $-152M | $200.0K | · | $75M | $108M | $100M | $161M | · | |
| Levered FCF | · | · | · | $-154M | $-3M | · | · | $104M | $97M | · | · |
Profitability
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 69.9% | 69.9% | · | · | · | · | · | · | · | · | · | |
| Operating Margin | -47.0% | -14.7% | -34.2% | -20.7% | -27.6% | · | 0.89% | 15.4% | 6.4% | 22.1% | · | |
| Net Margin | -44.4% | -15.2% | -35.0% | -16.5% | -3.9% | · | 0.54% | 17.0% | 2.8% | 16.6% | · | |
| Pretax Margin | -47.9% | -14.7% | -34.8% | -20.7% | -8.3% | · | 0.00% | 15.1% | 5.6% | 22.4% | · | |
| EBITDA Margin | -47.0% | -14.7% | -34.2% | -20.7% | -27.6% | · | 0.89% | 15.4% | 6.4% | 22.1% | · | |
| ROA | -42.2% | -11.7% | -22.4% | -8.9% | -2.0% | · | 0.34% | 11.0% | 2.1% | 15.2% | · | |
| ROE | -96.8% | -17.8% | -35.9% | -12.4% | -2.9% | · | 0.42% | 15.1% | 2.9% | 17.8% | · | |
| ROIC | -73.5% | -17.2% | -31.5% | -12.6% | -9.4% | · | · | 13.6% | 3.2% | 16.5% | · |
Liquidity & Solvency
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 2.5 | 1.8 | 2.0 | 2.0 | 2.4 | · | 3.0 | 3.2 | 1.5 | 4.3 | · | |
| Quick Ratio | 2.0 | 1.4 | 1.6 | 1.6 | 2.1 | · | 2.3 | 2.7 | 1.2 | 3.5 | · | |
| Debt / Equity | 0.3 | 0.1 | 0.0 | · | 0.0 | · | 0.2 | 0.0 | · | · | · | |
| LT Debt / Equity | 0.3 | 0.1 | 0.0 | · | 0.0 | · | 0.2 | 0.0 | · | · | · | |
| Interest Coverage | · | · | -88.8 | -43.9 | -28.9 | · | 0.6 | 37.1 | 8.2 | · | · |
Efficiency
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 1.0 | 0.8 | 0.6 | 0.5 | 0.5 | · | 0.6 | 0.6 | 0.7 | 0.9 | · | |
| Inventory Turnover | 8.5 | 10.2 | · | · | · | · | · | · | 3.6 | 4.2 | · | |
| Receivables Turnover | 7.0 | 7.1 | 7.0 | 7.0 | 7.6 | · | 7.3 | 8.2 | 7.8 | 8.5 | · |
Per Share
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Book Value / Share | $3.94 | $7.68 | $8.71 | $10.91 | $12.10 | · | $14.81 | $13.67 | $11.38 | $10.83 | · | |
| Revenue / Share | $8.90 | $9.24 | $9.10 | $8.42 | $8.85 | · | $11.20 | $10.73 | $11.21 | $10.27 | · | |
| Cash Flow / Share | $0.02 | $-0.10 | $-1.34 | $-1.32 | $0.23 | · | $1.10 | $1.61 | $1.54 | $2.27 | · | |
| Cash / Share | $1.60 | $1.12 | $1.47 | $0.70 | $3.23 | · | $1.27 | $1.57 | $1.50 | $0.99 | · | |
| EPS (TTM) | $-3.95 | $-1.41 | $-3.18 | $-1.39 | $-0.35 | · | $0.06 | $1.85 | $0.25 | $1.60 | $1.07 |
Growth Rates
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY | -1.6% | 11.2% | 11.0% | -1.8% | 24.0% | · | · | · | · | · | · | |
| Revenue CAGR 3Y | 6.7% | 6.6% | 10.6% | · | · | · | · | · | · | · | · | |
| Revenue CAGR 5Y | 8.2% | · | · | · | · | · | · | · | · | · | · |
Valuation (TTM)
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $824M | $838M | $753M | $678M | $691M | · | $851M | $744M | $729M | $740M | $722M | |
| Net Income TTM | $-366M | $-127M | $-263M | $-112M | $-27M | · | $5M | $133M | $17M | $117M | $80M | |
| Market Cap | $575M | $1.25B | $1.72B | $1.18B | $2.21B | · | $2.04B | $2.64B | $1.77B | $2.11B | · | |
| Enterprise Value | $545M | $1.19B | $1.62B | · | $1.87B | · | $2.14B | $2.47B | · | · | · | |
| P/E | -1.6 | -9.7 | -6.0 | -10.4 | -78.9 | · | 463.0 | 20.2 | 103.4 | 19.1 | 31.8 | |
| P/S | 0.7 | 1.5 | 2.3 | 1.7 | 3.2 | · | 2.4 | 3.5 | 2.4 | 2.9 | · | |
| P/B | 1.6 | 1.8 | 2.2 | 1.3 | 2.3 | · | 1.9 | 2.7 | 2.3 | 2.8 | · | |
| P / Tangible Book | 3.5 | 8.2 | 11.8 | 5.4 | 6.8 | · | · | · | · | · | · | |
| P / Cash Flow | 319.5 | -143.9 | -15.5 | -11.1 | 121.3 | · | 24.4 | 22.8 | 16.6 | 12.7 | · | |
| P / FCF | · | · | · | -7.8 | 11040.0 | · | 27.2 | 24.5 | 17.7 | 13.1 | · | |
| EV / EBITDA | -1.4 | -9.6 | -6.3 | · | -9.8 | · | 281.4 | 20.8 | · | · | · | |
| EV / FCF | · | · | · | · | 9341.0 | · | 28.5 | 22.9 | · | · | · | |
| EV / Revenue | 0.7 | 1.4 | 2.1 | · | 2.7 | · | 2.5 | 3.3 | · | · | · | |
| Earnings Yield | -64.2% | -10.3% | -16.6% | -9.6% | -1.3% | · | 0.22% | 5.0% | 0.97% | 5.2% | 3.1% |
Income Statement
| Metric | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $191M | $200M | $210M | $206M | $213M | $196M | $211M | $213M | $212M | $202M | $197M | $192M | $184M | $181M | $178M | $156M | |
| Cost of Revenue | $64M | $63M | $63M | $62M | $61M | $62M | $60M | $64M | $64M | $65M | $62M | $58M | $58M | $59M | $54M | $50M | |
| Gross Profit | $127M | $138M | $147M | $144M | $152M | $134M | $151M | $150M | $147M | $138M | · | · | · | · | · | · | |
| R&D Expense | $25M | $27M | $26M | $28M | $26M | $28M | $33M | $28M | $27M | $25M | $21M | $24M | $21M | $22M | $23M | $20M | |
| SG&A Expense | $58M | $62M | $56M | $68M | $67M | $66M | $63M | $69M | $72M | $71M | $-145M | $136M | $141M | $152M | $-120M | $130M | |
| Operating Expenses | $166M | $168M | $152M | $167M | $481M | $163M | $190M | $170M | $184M | $166M | $-8M | $252M | $297M | $233M | $28M | $201M | |
| Operating Income | $-39M | $-31M | $-6M | $-23M | $-329M | $-29M | $-39M | $-20M | $-36M | $-28M | $-31M | $-60M | $-114M | $-52M | $-52M | $-45M | |
| Interest Expense | · | · | · | · | · | · | · | · | · | $500.0K | · | $1M | $500.0K | $500.0K | · | $800.0K | |
| Interest Income | $400.0K | $700.0K | $800.0K | $500.0K | $200.0K | $300.0K | $300.0K | $400.0K | $400.0K | $600.0K | $700.0K | $600.0K | $500.0K | $700.0K | $1M | $1M | |
| Other Non-op | $0 | $0 | $400.0K | $400.0K | $-100.0K | $100.0K | $300.0K | $-800.0K | $-300.0K | $2M | $-700.0K | $-700.0K | $-2M | $-600.0K | $0 | $500.0K | |
| Pretax Income | $-43M | $-34M | $-9M | $-26M | $-331M | $-29M | $-39M | $-21M | $-37M | $-26M | $-32M | $-61M | $-116M | $-53M | $-52M | $-44M | |
| Income Tax | $600.0K | $0 | $-1M | $1M | $-100.0K | $-29M | $3M | $900.0K | $-500.0K | $100.0K | $-1M | $100.0K | $0 | $2M | $-10M | $-9M | |
| Net Income | $-43M | $-34M | $-8M | $-27M | $-330M | $-100.0K | $-42M | $-22M | $-37M | $-26M | $-31M | $-61M | $-116M | $-55M | $-42M | $-35M | |
| EPS (Basic) | $-0.46 | $-0.36 | $-0.09 | $-0.29 | $-3.57 | $0.00 | $-0.47 | $-0.24 | $-0.41 | $-0.29 | $-0.34 | $-0.75 | $-1.42 | $-0.67 | $-0.52 | $-0.43 | |
| EPS (Diluted) | $-0.46 | $-0.36 | $-0.09 | $-0.29 | $-3.57 | $0.00 | $-0.47 | $-0.24 | $-0.41 | $-0.29 | $-0.34 | $-0.75 | $-1.42 | $-0.67 | $-0.52 | $-0.43 | |
| Shares (Basic) | 94,800,000 | 93,700,000 | · | 93,100,000 | 92,500,000 | 91,400,000 | · | 90,900,000 | 90,600,000 | 89,900,000 | · | 81,900,000 | 81,700,000 | 81,300,000 | · | 80,700,000 | |
| Shares (Diluted) | 94,800,000 | 93,700,000 | · | 93,100,000 | 92,500,000 | 91,400,000 | · | 90,900,000 | 90,600,000 | 89,900,000 | · | 81,900,000 | 81,700,000 | 81,300,000 | · | 80,700,000 | |
| EBITDA | $-39M | $-31M | · | $-23M | $-329M | $-29M | · | $-20M | $-36M | $-28M | · | $-60M | $-114M | $-52M | · | $-45M |
Balance Sheet
| Metric | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $115M | $124M | $150M | $145M | $74M | $92M | $102M | $100M | $92M | $97M | $132M | $76M | $103M | $54M | $57M | $111M | |
| Short-term Investments | · | · | · | · | · | · | · | $0 | $5M | $7M | · | $10M | $19M | $25M | · | $82M | |
| Receivables | $110M | $124M | $115M | $118M | $137M | $120M | $121M | $126M | $118M | $118M | · | $115M | $112M | $119M | · | $102M | |
| Inventory | $31M | $28M | $31M | $32M | $29M | $28M | $28M | $26M | $26M | $25M | · | $25M | $22M | $22M | · | $20M | |
| Prepaid Expense | $32M | $35M | $25M | $36M | $30M | $32M | $30M | $24M | $22M | $25M | · | $21M | $21M | $24M | · | $20M | |
| Current Assets | $289M | $313M | $333M | $345M | $284M | $287M | $298M | $293M | $292M | $290M | · | $265M | $294M | $262M | · | $352M | |
| PP&E (Net) | $109M | $112M | $114M | $111M | $113M | $114M | $117M | $115M | $116M | $118M | · | $121M | $112M | $96M | · | $68M | |
| PP&E (Gross) | $201M | $202M | $202M | $195M | $192M | $198M | $227M | $233M | $231M | $229M | · | $239M | $227M | $208M | · | $176M | |
| Accum. Depreciation | $92M | $90M | $88M | $83M | $79M | $84M | $110M | $117M | $114M | $111M | · | $118M | $115M | $112M | · | $108M | |
| Goodwill | $47M | $47M | $52M | $52M | $52M | $286M | $286M | $286M | $286M | $287M | · | $287M | $287M | $287M | · | $236M | |
| Intangibles | $139M | $146M | $153M | $163M | $170M | $258M | $262M | $312M | $320M | $341M | · | $357M | $359M | $369M | · | $371M | |
| Other Non-current Assets | $5M | $6M | $6M | $7M | $7M | $8M | $8M | $16M | $15M | $15M | · | $16M | $22M | $18M | · | $8M | |
| Total Assets | $639M | $674M | $707M | $728M | $677M | $1.01B | $1.03B | $1.08B | $1.09B | $1.11B | · | $1.15B | $1.19B | $1.17B | · | $1.21B | |
| Accounts Payable | $30M | $33M | $30M | $32M | $31M | $28M | $32M | $30M | $33M | $33M | · | $34M | $40M | $36M | · | $30M | |
| Accrued Liabilities | $93M | $90M | $97M | $108M | $101M | $112M | $119M | $111M | $98M | $99M | · | $158M | $164M | $92M | · | $85M | |
| Current Liabilities | $131M | $130M | $134M | $148M | $200M | $151M | $164M | $154M | $149M | $146M | · | $209M | $221M | $143M | · | $129M | |
| Capital Leases | $82M | $84M | $83M | $85M | $86M | $87M | $88M | $91M | $91M | $94M | · | $145M | $148M | $146M | · | $123M | |
| Deferred Tax | · | · | · | · | · | · | · | · | · | · | · | $3M | $4M | $4M | · | $10M | |
| Other Non-current Liabilities | $1M | $2M | $2M | $2M | $2M | $2M | $2M | $34M | $35M | $41M | · | $40M | $11M | $12M | · | $5M | |
| Total Liabilities | $335M | $336M | $339M | $355M | $289M | $301M | $326M | $350M | $345M | $350M | · | $466M | $452M | $334M | · | $295M | |
| Long-term Debt | $121M | $120M | $120M | $120M | $59M | · | · | · | · | · | · | · | · | $0 | · | $0 | |
| Total Debt | $121M | $120M | · | $120M | $59M | $59M | · | $39M | $39M | $39M | · | $38M | $38M | · | · | · | |
| Common Stock | $1M | $900.0K | $900.0K | $900.0K | $900.0K | $900.0K | $900.0K | $900.0K | $900.0K | $900.0K | · | $800.0K | $800.0K | $800.0K | · | $800.0K | |
| Retained Earnings | $-1.20B | $-1.16B | $-1.12B | $-1.11B | $-1.09B | $-757M | $-757M | $-714M | $-692M | $-656M | · | $-598M | $-537M | $-421M | · | $-324M | |
| AOCI | $800.0K | $700.0K | $800.0K | $-100.0K | $-100.0K | $-600.0K | $-800.0K | $-100.0K | $-4M | $-4M | · | $-5M | $-5M | $-7M | · | $-11M | |
| Stockholders' Equity | $304M | $337M | $368M | $373M | $388M | $705M | $701M | $732M | $740M | $760M | $783M | $683M | $735M | $835M | $886M | $917M | |
| Liabilities + Equity | $639M | $674M | $707M | $728M | $677M | $1.01B | $1.03B | $1.08B | $1.09B | $1.11B | · | $1.15B | $1.19B | $1.17B | · | $1.21B | |
| Shares Outstanding | 95,600,000 | 94,400,000 | 93,500,000 | 93,100,000 | 93,100,000 | 92,200,000 | 91,300,000 | 91,000,000 | 90,900,000 | 90,500,000 | 89,900,000 | 82,100,000 | 81,900,000 | 81,500,000 | 81,200,000 | 80,900,000 |
Cash Flow
| Metric | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $12M | $12M | $13M | $13M | $14M | $14M | $15M | $16M | $15M | $16M | $15M | $14M | $13M | $19M | $14M | $13M | |
| Stock-based Comp | $7M | $6M | $3M | $12M | $11M | $10M | $11M | $12M | $14M | $12M | $10M | $12M | $11M | $8M | $8M | $9M | |
| Amort. of Intangibles | $8M | $8M | $8M | $8M | $9M | $9M | $10M | $10M | $11M | $11M | $11M | $11M | $11M | $11M | $10M | $10M | |
| Operating Cash Flow | $-8M | $-16M | $11M | $21M | $-14M | $-16M | $7M | $700.0K | $3M | $-19M | $-55M | $-22M | $-900.0K | $-33M | $-7M | $-2M | |
| CapEx | · | · | · | · | · | · | · | · | · | · | · | · | $19M | $24M | · | $18M | |
| Investing Cash Flow | $-3M | $-6M | $-6M | $-6M | $-7M | $-8M | $-6M | $8M | $-6M | $-7M | $-12M | $-2M | $12M | $35M | $-36M | $11M | |
| Financing Cash Flow | $2M | $-3M | $-8M | $56M | $3M | $14M | $2M | $-3M | $2M | $-9M | $122M | $-2M | $38M | $-5M | $-2M | $-4M | |
| Net Change in Cash | $-9M | $-25M | $-4M | $71M | $-17M | $-11M | $2M | $9M | $-4M | $-35M | $56M | $-28M | $50M | $-3M | $-44M | $5M | |
| Taxes Paid | $400.0K | $-12M | · | · | $0 | $300.0K | · | · | · | · | · | · | · | · | · | · | |
| Free Cash Flow | · | · | · | · | · | · | · | · | · | · | · | · | · | $-57M | · | · | |
| Levered FCF | · | · | · | · | · | · | · | · | · | · | · | · | · | $-57M | · | · |
Profitability
| Metric | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 66.6% | 68.7% | · | 69.9% | 71.2% | 68.5% | · | · | · | · | · | · | · | · | · | · | |
| Operating Margin | -20.4% | -15.3% | · | -11.3% | -154.5% | -14.8% | · | -9.4% | -17.3% | -13.8% | · | -31.3% | -62.0% | -28.8% | · | -28.8% | |
| Net Margin | -22.7% | -17.0% | · | -13.3% | -155.1% | -0.05% | · | -10.4% | -17.3% | -12.9% | · | -31.9% | -63.3% | -30.2% | · | -22.4% | |
| Pretax Margin | -22.3% | -17.0% | · | -12.7% | -155.1% | -15.0% | · | -9.9% | -17.6% | -12.8% | · | -31.9% | -63.3% | -29.0% | · | -28.3% | |
| EBITDA Margin | -20.4% | -15.3% | · | -11.3% | -154.5% | -14.8% | · | -9.4% | -17.3% | -13.8% | · | -31.3% | -62.0% | -28.8% | · | -28.8% | |
| ROA | -6.6% | -4.1% | · | -3.0% | -37.5% | -0.01% | · | -2.0% | -3.2% | -2.3% | · | -5.2% | -9.7% | -4.5% | · | -2.8% | |
| ROE | -12.5% | -6.5% | · | -5.0% | -58.6% | -0.01% | · | -3.1% | -5.0% | -3.3% | · | -7.7% | -13.8% | -6.1% | · | -3.7% | |
| ROIC | -9.3% | -6.7% | · | -5.0% | -73.5% | -0.01% | · | -2.7% | -4.6% | -3.5% | · | -8.3% | -14.7% | -6.5% | · | -3.9% |
Liquidity & Solvency
| Metric | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 2.2 | 2.4 | · | 2.3 | 1.4 | 1.9 | · | 1.9 | 2.0 | 2.0 | · | 1.3 | 1.3 | 1.8 | · | 2.7 | |
| Quick Ratio | 1.7 | 1.9 | · | 1.8 | 1.1 | 1.4 | · | 1.5 | 1.4 | 1.5 | · | 1.0 | 1.1 | 1.4 | · | 2.3 | |
| Debt / Equity | 0.4 | 0.4 | · | 0.3 | 0.2 | 0.1 | · | 0.1 | 0.1 | 0.1 | · | 0.1 | 0.1 | · | · | · | |
| LT Debt / Equity | 0.4 | 0.4 | · | 0.3 | 0.0 | 0.1 | · | 0.1 | 0.1 | 0.1 | · | 0.1 | 0.1 | · | · | · | |
| Interest Coverage | · | · | · | · | · | · | · | · | · | -55.8 | · | -60.1 | -227.4 | -104.4 | · | -56.2 |
Efficiency
| Metric | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.3 | 0.2 | · | 0.2 | 0.2 | 0.2 | · | 0.2 | 0.2 | 0.2 | · | 0.2 | 0.2 | 0.1 | · | 0.1 | |
| Inventory Turnover | 2.1 | 2.2 | · | 2.1 | 2.2 | 2.3 | · | 2.5 | 2.7 | 2.8 | · | 2.6 | 3.1 | 3.2 | · | · | |
| Receivables Turnover | 1.5 | 1.6 | · | 1.7 | 1.7 | 1.6 | · | 1.8 | 1.8 | 1.7 | · | 1.8 | 1.7 | 1.6 | · | 1.6 |
Per Share
| Metric | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Book Value / Share | $3.18 | $3.57 | · | $4.00 | $4.17 | $7.65 | · | $8.04 | $8.15 | $8.40 | · | $8.32 | $8.98 | $10.25 | · | $11.33 | |
| Revenue / Share | $2.01 | $2.14 | · | $2.21 | $2.30 | $2.14 | · | $2.35 | $2.33 | $2.25 | · | $2.34 | $2.25 | $2.23 | · | $1.94 | |
| Cash Flow / Share | · | $-0.17 | · | · | · | $-0.18 | · | · | · | $-0.21 | · | · | · | $-0.41 | · | · | |
| Cash / Share | $1.21 | $1.32 | · | $1.56 | $0.80 | $1.00 | · | $1.10 | $1.02 | $1.07 | · | $0.93 | $1.26 | $0.66 | · | $1.37 | |
| EPS (TTM) | $-1.20 | $-4.31 | · | $-4.33 | $-4.28 | $-1.12 | · | $-1.28 | $-1.79 | $-2.80 | · | $-3.36 | $-3.04 | $-1.80 | · | $-0.94 |
Valuation (TTM)
| Metric | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $807M | $829M | · | $825M | $833M | $831M | · | $824M | $802M | $774M | · | $734M | $699M | $695M | · | $661M | |
| Net Income TTM | $-113M | $-400M | · | $-400M | $-395M | $-101M | · | $-116M | $-155M | $-235M | · | $-274M | $-248M | $-146M | · | $-77M | |
| Market Cap | $546M | $425M | · | $673M | $494M | $818M | · | $2.49B | $2.22B | $1.93B | · | $1.32B | $1.90B | $1.89B | · | $1.54B | |
| Enterprise Value | $551M | $421M | · | $647M | $479M | $785M | · | $2.43B | $2.16B | $1.86B | · | $1.27B | $1.82B | · | · | · | |
| P/E | -4.8 | -1.0 | · | -1.7 | -1.2 | -7.9 | · | -21.4 | -13.7 | -7.6 | · | -4.8 | -7.6 | -12.9 | · | -20.3 | |
| P/S | 0.7 | 0.5 | · | 0.8 | 0.6 | 1.0 | · | 3.0 | 2.8 | 2.5 | · | 1.8 | 2.7 | 2.7 | · | 2.3 | |
| P/B | 1.8 | 1.3 | · | 1.8 | 1.3 | 1.2 | · | 3.4 | 3.0 | 2.5 | · | 1.9 | 2.6 | 2.3 | · | 1.7 | |
| P / Tangible Book | 4.6 | 2.9 | · | 4.3 | 3.0 | 5.1 | · | 18.8 | 16.5 | 14.6 | · | 32.8 | 21.3 | 10.6 | · | 5.0 | |
| P / Cash Flow | · | -27.1 | · | · | · | -50.2 | · | · | · | -103.7 | · | · | · | -57.0 | · | · | |
| EV / Revenue | 0.7 | 0.5 | · | 0.8 | 0.6 | 0.9 | · | 3.0 | 2.7 | 2.4 | · | 1.7 | 2.6 | · | · | · | |
| Earnings Yield | -21.0% | -95.8% | · | -59.9% | -80.6% | -12.6% | · | -4.7% | -7.3% | -13.1% | · | -20.9% | -13.1% | -7.8% | · | -4.9% |
Most recent period on the left · null values shown as ·
Financial Statements Income statement, balance sheet, cash flow — annual, last 5 years
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Revenue | $824M | $838M | $753M | $678M | $691M |
| Gross Margin % | 69.9% | 69.9% | · | · | · |
| Operating Margin % | -47.0% | -14.7% | -34.2% | -20.7% | -27.6% |
| Net Income | $-366M | $-127M | $-263M | $-112M | $-27M |
| Diluted EPS | $-3.95 | $-1.41 | $-3.18 | $-1.39 | $-0.35 |
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Debt / Equity | 0.3 | 0.1 | 0.0 | · | 0.0 |
| Current Ratio | 2.5 | 1.8 | 2.0 | 2.0 | 2.4 |
| Quick Ratio | 2.0 | 1.4 | 1.6 | 1.6 | 2.1 |
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Free Cash Flow | · | · | · | $-152M | $200.0K |
Institutional owners (13F) 217 filers · $557.6M total · As of June 30, 2026
Institutions that report holding this stock in their quarterly SEC Form 13F. Long positions only; a single filer may appear twice for separate option legs. Large offsetting put/call legs typically reflect market-making or hedged inventory, not directional conviction.
| New positions | Exited positions | Increased | Decreased | Net shares change |
|---|---|---|---|---|
| 46 (+9 vs prior Q) | 45 (0 vs prior Q) | 75 (+2 vs prior Q) | 56 (-7 vs prior Q) | -123.4M |
Compared to Q1 2026. SEC Form 13F filings are due within 45 days of quarter-end plus a short buffer for late filers — quarters still inside that window are skipped in favor of the most recent fully-reported pair.
| Institution | Value | Shares | % of tracked 13F | Type |
|---|---|---|---|---|
| BlackRock, Inc. | $62,184,412 | 10,890,440 | 11.15% | Shares |
| VANGUARD GROUP INC | $50,586,032 | 8,225,371 | 9.07% | Shares |
| MILLENNIUM MANAGEMENT LLC | $37,802,324 | 6,620,372 | 6.78% | Shares |
| Vestal Point Capital, LP | $32,746,850 | 5,735,000 | 5.87% | Shares |
| STATE STREET CORP | $28,464,693 | 4,985,060 | 5.10% | Shares |
| D. E. Shaw & Co., Inc. | $26,163,694 | 4,582,083 | 4.69% | Shares |
| VANGUARD CAPITAL MANAGEMENT LLC | $23,304,657 | 4,081,376 | 4.18% | Shares |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $17,584,916 | 3,079,670 | 3.15% | Shares |
| AQR CAPITAL MANAGEMENT LLC | $15,797,792 | 2,766,689 | 2.83% | Shares |
| MORGAN STANLEY | $14,167,103 | 2,481,104 | 2.54% | Shares |
| GEODE CAPITAL MANAGEMENT, LLC | $13,800,073 | 2,416,197 | 2.47% | Shares |
| GOLDMAN SACHS GROUP INC | $11,744,574 | 2,056,843 | 2.11% | Shares |
| JACOBS LEVY EQUITY MANAGEMENT, INC | $10,800,619 | 1,891,527 | 1.94% | Shares |
| Camber Capital Management LP | $10,620,000 | 2,000,000 | 1.90% | Shares |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | $9,939,934 | 1,740,794 | 1.78% | Shares |
| Qube Research & Technologies Ltd | $9,511,918 | 1,665,835 | 1.71% | Shares |
| FEDERATED HERMES, INC. | $8,966,493 | 1,570,314 | 1.61% | Shares |
| TWO SIGMA INVESTMENTS, LP | $8,894,621 | 1,557,727 | 1.60% | Shares |
| Nuveen, LLC | $8,825,085 | 1,545,549 | 1.58% | Shares |
| MACKENZIE FINANCIAL CORP | $8,768,858 | 1,535,702 | 1.57% | Shares |
| CITADEL ADVISORS LLC | $8,757,335 | 1,533,684 | 1.57% | Shares |
| Connor, Clark & Lunn Investment Management Ltd. | $8,038,880 | 1,407,860 | 1.44% | Shares |
| Aberdeen Group plc | $7,474,007 | 1,308,933 | 1.34% | Shares |
| MARSHALL WACE, LLP | $6,982,210 | 1,222,804 | 1.25% | Shares |
| DIMENSIONAL FUND ADVISORS LP | $6,008,336 | 1,051,996 | 1.08% | Shares |
| Assenagon Asset Management S.A. | $5,889,659 | 1,031,464 | 1.06% | Shares |
| NORTHERN TRUST CORP | $5,246,667 | 918,856 | 0.94% | Shares |
| Man Group plc | $5,188,865 | 908,733 | 0.93% | Shares |
| BANK OF AMERICA CORP /DE/ | $5,149,827 | 901,896 | 0.92% | Shares |
| ARROWSTREET CAPITAL, LIMITED PARTNERSHIP | $4,469,588 | 782,765 | 0.80% | Shares |
| FMR LLC | $4,409,357 | 772,217 | 0.79% | Shares |
| Cubist Systematic Strategies, LLC | $3,840,296 | 531,161 | 0.69% | Shares |
| VANGUARD FIDUCIARY TRUST CO | $3,555,172 | 622,622 | 0.64% | Shares |
| PRUDENTIAL FINANCIAL INC | $3,523,430 | 617,063 | 0.63% | Shares |
| WELLS FARGO & COMPANY/MN | $3,097,426 | 542,456 | 0.56% | Shares |
| AMH Equity Ltd | $2,892,000 | 400,000 | 0.52% | Shares |
| Walleye Capital LLC | $2,653,134 | 464,647 | 0.48% | Shares |
| BNP PARIBAS FINANCIAL MARKETS | $2,567,998 | 449,737 | 0.46% | Shares |
| OP Asset Management Ltd | $2,567,313 | 449,617 | 0.46% | Shares |
| STATE OF WISCONSIN INVESTMENT BOARD | $2,341,831 | 410,128 | 0.42% | Shares |
| Squarepoint Ops LLC | $2,190,921 | 383,699 | 0.39% | Shares |
| TWO SIGMA ADVISERS, LP | $2,092,230 | 340,200 | 0.38% | Shares |
| Bank of New York Mellon Corp | $1,929,647 | 337,942 | 0.35% | Shares |
| Militia Capital Management LLC | $1,720,994 | 301,400 | 0.31% | Shares |
| UBS Group AG | $1,680,715 | 294,346 | 0.30% | Shares |
| Invesco Ltd. | $1,519,191 | 266,058 | 0.27% | Shares |
| AMERIPRISE FINANCIAL INC | $1,489,082 | 260,785 | 0.27% | Shares |
| IEQ CAPITAL, LLC | $1,455,302 | 254,869 | 0.26% | Shares |
| Point72 Asset Management, L.P. | $1,363,411 | 238,776 | 0.24% | Shares |
| XTX Topco Ltd | $1,353,407 | 237,024 | 0.24% | Shares |
Company insiders 63 insiders · 39 officers · 18 directors
| Insider | Role | Last activity | Shares owned | Buys 12m | Sells 12m | Net 12m |
|---|---|---|---|---|---|---|
| Samraat S. Raha | President and CEO | June 11, 2026 A | 1,068,083 | 1 | 0 | $200,000 |
| Paul J Diaz | President and CEO | March 24, 2025 F | 891,844 | 0 | 0 | $0 |
| Benjamin Richard Wheeler | Chief Financial Officer | Sept. 21, 2026 F | 287,193 | 0 | 0 | $0 |
| Scott J. Leffler | Chief Financial Officer | March 14, 2025 F | 218,393 | 0 | 0 | $0 |
| Richard Bryan Riggsbee | Chief Financial Officer | Dec. 1, 2023 S | 291,812 | 0 | 0 | $0 |
| Jay M Moyes | Chief Financial Officer | Oct. 15, 2007 M | 25,282 | 0 | 0 | $0 |
| Bernard Tobin | President Crescendo BioScience | Sept. 30, 2019 D | 160,636 | 0 | 0 | $0 |
| Ralph L Mcdade | President Myriad RBM, Inc. | Sept. 30, 2019 D | 142,095 | 0 | 0 | $0 |
| Virginia Drosos | President Assurex Health | Sept. 14, 2016 A | 50,000 | 0 | 0 | $0 |
| Peter D Meldrum | President & C.E.O. | May 6, 2015 M | 10,424 | 0 | 0 | $0 |
| Craig T Benson | President, Myriad RBM | Sept. 17, 2013 A | · | 0 | 0 | $0 |
| Gregory C Critchfield | President Myriad Genetic Labs | Sept. 15, 2009 A | 129,546 | 0 | 0 | $0 |
| Mark Verratti | Chief Operating Officer | April 14, 2026 F | 629,646 | 0 | 0 | $0 |
| Nicole Lambert | Chief Operating Officer | Oct. 9, 2023 F | 223,993 | 0 | 0 | $0 |
| Alexander Ford | Chief Operating Officer | Sept. 30, 2020 D | 169,040 | 0 | 0 | $0 |
| Vishal Sikri | EVP, Commercial | Sept. 16, 2026 A | 351,224 | 0 | 0 | $0 |
| Jennifer Lynne Fox | Chief Legal Officer | Sept. 3, 2026 F | 305,964 | 0 | 0 | $0 |
| Brian J Donnelly | Chief Commerical Officer | June 11, 2026 A | 573,363 | 0 | 0 | $0 |
| Raj Jampa | Chief Technology Officer | June 1, 2026 A | 251,889 | 0 | 0 | $0 |
| Dale Muzzey | Chief Scientific Officer | April 14, 2026 F | 326,310 | 0 | 0 | $0 |
| Kevin Richard Haas | Chief Technology Officer | March 15, 2026 F | 180,022 | 0 | 0 | $0 |
| Shereen Solaiman | Chief People Officer | March 14, 2026 F | 267,801 | 0 | 0 | $0 |
| Natalie Munk | Chief Accounting Officer | Sept. 21, 2025 F | 45,167 | 0 | 0 | $0 |
| Margaret Ancona | EVP, Strategy & Transformation | Sept. 21, 2025 F | 127,726 | 0 | 0 | $0 |
| Pamela Wong | Chief Legal Officer | March 22, 2024 F | 65,002 | 0 | 0 | $0 |
| Jayne B. Hart | Chief People Officer | Oct. 9, 2022 F | 172,561 | 0 | 0 | $0 |
| Eric Santa | Chief Growth Officer | April 1, 2022 F | 56,734 | 0 | 0 | $0 |
| Jerry S Lanchbury | Chief Scientific Officer | Oct. 9, 2021 F | 264,324 | 0 | 0 | $0 |
| Paul Parkinson | EVP Strategy and Innovation | March 24, 2021 A | 87,407 | 0 | 0 | $0 |
| Benjamin Jackson | E.V.P., General Counsel | March 24, 2021 A | 107,029 | 0 | 0 | $0 |
| Gary A. King | Exec. VP International Ops | Sept. 30, 2019 D | 148,397 | 0 | 0 | $0 |
| Richard M Marsh | E.V.P., General Counsel | Sept. 30, 2018 D | 144,174 | 0 | 0 | $0 |
| Richard Wenstrup | Chief Medical Officer | Sept. 30, 2016 D | 50,207 | 0 | 0 | $0 |
| Ronald S. Rogers | Exec VP Corp Communications | Sept. 17, 2014 A | 16,000 | 0 | 0 | $0 |
| Robert Gardner Harrison | Chief Information Officer | Sept. 17, 2014 A | 25,844 | 0 | 0 | $0 |
| Mark H Skolnick | Chief Scientific Officer | Nov. 5, 2009 M | 34,000 | 0 | 0 | $0 |
| Adrian N Hobden | Pres. Myriad Pharmaceuticals | June 8, 2009 M | 234,071 | 0 | 0 | $0 |
| William A Hockett III | V. P. of Corp Communications | Sept. 10, 2008 A | 9,001 | 0 | 0 | $0 |
| George S Simon | V.P. Business Development | Jan. 12, 2007 M | 2,278 | 0 | 0 | $0 |
| Rashmi Kumar | Director | June 8, 2026 S | 171,889 | 0 | 1 | $-66,900 |
| Mark Steven Davis | Director | June 4, 2026 A | 106,665 | 0 | 0 | $0 |
| Lee Nisley Newcomer | Director | June 4, 2026 A | 191,842 | 0 | 0 | $0 |
| Daniel Skovronsky | Director | June 4, 2026 A | 195,507 | 0 | 0 | $0 |
| Colleen F Reitan | Director | June 4, 2026 A | 152,030 | 0 | 0 | $0 |
| Louise S. Phanstiel | Director | June 4, 2026 A | 341,652 | 3 | 0 | $494,548 |
| Heinrich Dreismann | Director | June 4, 2026 A | 231,145 | 0 | 0 | $0 |
| Paul Bisaro | Director | June 4, 2026 A | 157,142 | 1 | 0 | $27,600 |
| Dennis Langer | Director | June 2, 2022 A | 106,802 | 0 | 0 | $0 |
| Lawrence C Best | Director | Dec. 5, 2019 A | 60,790 | 0 | 0 | $0 |
| Linda S Wilson | Director | Jan. 7, 2010 M | 2,500 | 0 | 0 | $0 |
| Gerald P. Belle | Director | Nov. 4, 2009 A | 1,200 | 0 | 0 | $0 |
| Dale A Stringfellow | Director | Feb. 17, 2005 A | · | 0 | 0 | $0 |
| Arthur H Hayes JR | Director | Nov. 12, 2003 A | · | 0 | 0 | $0 |
| Daniel K Spiegelman | · | June 4, 2024 S | 32,917 | 0 | 0 | $0 |
| Heinrich Dreismann | · | June 3, 2021 A | 83,527 | 0 | 0 | $0 |
| Walter Gilbert PHD | · | Dec. 13, 2019 P | 54,150 | 0 | 0 | $0 |
| John T Henderson | · | Dec. 5, 2019 A | 76,040 | 0 | 0 | $0 |
| Mark Christopher Capone | · | Sept. 30, 2019 D | 522,216 | 0 | 0 | $0 |
| Walter Lloyd Sanders | · | Sept. 30, 2018 D | 36,195 | 0 | 0 | $0 |
| James S Evans | · | Sept. 30, 2014 M | 48,128 | 0 | 0 | $0 |
| Wayne W Laslie | · | May 8, 2009 M | 44,260 | 0 | 0 | $0 |
| Robert S Attiyeh | · | Nov. 13, 2008 A | 3,000 | 0 | 0 | $0 |
| Arthur Hull Hayes JR | · | Nov. 15, 2007 A | 0 | 0 | 0 | $0 |
Insiders from SEC Form 3/4/5 filings; net = open-market P/S only
ETF ownership Held by 30 ETFs
Weight reflects direct equity holdings (N-PORT) only; leveraged or derivative-based funds may hold additional swap exposure not shown.
| Fund | Weight | Units | As of | Source |
|---|---|---|---|---|
| QQQS · Invesco Exchange-Traded Fund Trust … | 0.66% | 37,225 SH | Oct. 2, 2026 | Daily |
| HAPS · Harbor ETF Trust | 0.16% | 97,428 NS | July 31, 2026 | N-PORT |
| VFMF · VANGUARD WELLINGTON FUND | 0.10% | 117,614 SH | Aug. 19, 2026 | Daily |
| VFQY · VANGUARD WELLINGTON FUND | 0.08% | 62,341 SH | Aug. 19, 2026 | Daily |
| VFVA · VANGUARD WELLINGTON FUND | 0.06% | 86,916 SH | Aug. 19, 2026 | Daily |
| LABU · Direxion Shares ETF Trust | 0.06% | 102,468 NS | July 31, 2026 | N-PORT |
| VTWV · VANGUARD SCOTTSDALE FUNDS | 0.03% | 80,572 SH | Aug. 19, 2026 | Daily |
| OMFS · Invesco Exchange-Traded Self-Indexe… | 0.03% | 17,023 SH | Oct. 2, 2026 | Daily |
| PRFZ · Invesco Exchange-Traded Fund Trust | 0.03% | 171,149 SH | Oct. 2, 2026 | Daily |
| IBB · iShares Trust | 0.02% | 665,004 SH | Sept. 11, 2026 | Daily |
| VTWO · VANGUARD SCOTTSDALE FUNDS | 0.02% | 532,111 SH | Aug. 19, 2026 | Daily |
| PWS · Pacer Funds Trust | 0.02% | 1,400 NS | July 31, 2026 | N-PORT |
| IWM · iShares Trust | 0.01% | 2,371,823 SH | Sept. 11, 2026 | Daily |
| VXF · VANGUARD INDEX FUNDS | 0.01% | 1,108,712 SH | Aug. 19, 2026 | Daily |
| VHT · VANGUARD WORLD FUND | 0.01% | 270,010 SH | Aug. 19, 2026 | Daily |
| RSSL · Global X Funds | 0.01% | 44,186 NS | July 31, 2026 | N-PORT |
| JPSE · J.P. Morgan Exchange-Traded Fund Tr… | 0.01% | 16,657 NS | July 31, 2026 | N-PORT |
| DFAS · Dimensional ETF Trust | 0.00% | 190,558 NS | July 31, 2026 | N-PORT |
| DXUV · Dimensional ETF Trust | 0.00% | 2,479 NS | July 31, 2026 | N-PORT |
| DCOR · Dimensional ETF Trust | 0.00% | 13,787 NS | July 31, 2026 | N-PORT |
| DFSU · Dimensional ETF Trust | 0.00% | 9,100 NS | July 31, 2026 | N-PORT |
| DFAU · Dimensional ETF Trust | 0.00% | 20,708 NS | July 31, 2026 | N-PORT |
| ITOT · iShares Trust | 0.00% | 125,596 SH | Sept. 11, 2026 | Daily |
| IWV · iShares Trust | 0.00% | 23,376 SH | Sept. 3, 2026 | Daily |
| DFUS · Dimensional ETF Trust | 0.00% | 21,310 NS | July 31, 2026 | N-PORT |
| DFAC · Dimensional ETF Trust | 0.00% | 47,694 NS | July 31, 2026 | N-PORT |
| VTI · VANGUARD INDEX FUNDS | 0.00% | 2,881,677 SH | Aug. 19, 2026 | Daily |
| VTHR · VANGUARD SCOTTSDALE FUNDS | 0.00% | 7,148 SH | Aug. 19, 2026 | Daily |
| IWN · iShares Trust | · | 854,602 SH | Sept. 11, 2026 | Daily |
| SMLF · iShares Trust | · | 186,725 SH | Sept. 11, 2026 | Daily |
MYGN Analyst Consensus Bullish and bearish analyst opinions, 12-month price target, upside
12-Month Price Target
9 analysts · 2026-09-28Mean target $3.37 -25.8%
Peer comparison (GICS sub-industry) Key metrics vs sector peers
FY basis, prices as of each company's last fiscal year-end close.
| Ticker | Market Cap | P/E | Rev YoY | Net Margin | ROE | Gross Margin |
|---|---|---|---|---|---|---|
| MYGN | $575M | -1.6 | -1.6% | -44.4% | -96.8% | 69.9% |
| OVID | $212M | -4.0 | 1181.3% | -240.1% | -18.7% | · |
| ASMB | $539M | -61.8 | 153.5% | -8.5% | -5.5% | · |
| TECX | $391M | -5.2 | · | · | -27.7% | · |
| DMAC | $428M | · | · | · | -78.7% | · |
| SPRY | $1.16B | -6.7 | -5.5% | -203.3% | -111.8% | · |
| EDIT | $201M | -1.1 | 25.4% | -395.0% | -688.8% | · |
| EIKN | · | · | · | · | · | · |
| GALT | $271M | -8.7 | · | · | 25.0% | · |
| RCEL | $105M | -2.0 | 11.5% | -67.8% | 328.9% | 82.1% |
Latest News Recent headlines mentioning this company
My Metrics Your personal watchlist — selected rows from Full Fundamentals
Pick the metrics that matter to you — click the + next to any row in Full Fundamentals above.
Your selection is saved and follows you across all tickers.